Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound

Patent metadata

Field	Value
Publication number	US-9795678-B2
Application number	US-201514712696-A
Country	US
Kind code	B2
Filing date	May 14, 2015
Priority date	May 14, 2014
Publication date	Oct 24, 2017
Grant date	Oct 24, 2017

Abstract

A composition, in the form of an aqueous solution, including insulin in hexameric form, at least one substituted anionic compound of non-saccharide structure and at least one polyanionic compound other than the substituted anionic compound.

First claim

The invention claimed is:

1. A composition, in the form of an aqueous solution, comprising insulin in hexameric form, at least one substituted anionic compound of non-saccharide structure and at least one polyanionic compound other than said substituted anionic compound, wherein the substituted anionic compound corresponds to formula I below:

wherein
R represents a saturated or unsaturated, linear, branched or cyclic hydrocarbon-based radical comprising from 1 to 12 carbon atoms, optionally comprising at least one function chosen from ether, alcohol and carboxylic acid functions,
AA is a radical resulting from an aromatic amino acid comprising a phenyl group or an indole group, which is substituted or not substituted, or an aromatic amino acid derivative comprising a phenyl group or an indole group, which is substituted or not substituted, said radical AA bearing at least one free acid function,
E represents an at least divalent radical, comprising from 2 to 6 carbon atoms,
F, F′ and F″ represent, independently of each other, a function chosen from amide, carbamate and urea functions, F and F″ being functions resulting from a reaction involving the amine of the aromatic amino acid, the precursor of the radical AA, F′ being a function involving a reactive function of the precursor of R and a reactive function of the precursor of E,
p being an integer between 1 and 3,
m is an integer between 0 and 6; n is an integer between 0 and 6; m+n is an integer between 1 and 6;

said compound comprising at least two carboxylic acid functions in the form of a salt of an alkali metal chosen from Na + and K + .

2. The composition as claimed in claim 1 , wherein the substituted anionic compound is chosen from the compounds of formula I wherein the radical —R— is chosen from radicals comprising 1 to 12 carbon atoms, of formula IV:

wherein q and r are integers between 0 and 12, r is an integer between 0 and 3 and 1≦q+r*t≦12, a is equal to 0 or 1, the groups R q1 , R q2 , R r1 and R r2 are, independently of each other, chosen from H, —OH and —COOH, if a=0, then t=0 and when q≧1 and/or t≧1, then the radicals R q1 and R q2 and the radicals R r1 and R r2 are identical or different from one carbon to another.

3. The composition as claimed in claim 1 , wherein the substituted anionic compound is chosen from the compounds of formula I wherein the radical AA is resulting from an aromatic amino acid comprising a phenyl or an indole, which is substituted or not substituted, or from an aromatic amino acid derivative comprising a phenyl or an indole, which is substituted or not substituted, most particularly, the radical AA is resulting from an aromatic amino acid comprising a phenyl or an indole, which is substituted or not substituted.

4. The composition as claimed in claim 1 , wherein the substituted anionic compound is chosen from the compounds of formula I wherein the radical E is resulting from a linear or branched alkyl compound comprising at least two functions chosen from the group consisting of OH, —COOH and —NH 2 .

5. The composition as claimed in claim 1 , wherein the substituted anionic compound is chosen from the compounds of formula I wherein n=0 and corresponds to formula II:

wherein:
AA, F and R have the definitions given above,
1≦m≦6.

6. The composition as claimed in claim 1 , wherein the substituted anionic compound is chosen from the compounds of formula I wherein m=0 and corresponds to formula III:

wherein:
AA, E, F′, F″, p and R have the definitions given above,
1≦n≦6.

7. The composition as claimed in claim 1 , wherein the mole ratios of substituted anionic compound/insulin are between 0.6 and 120.

8. The composition as claimed in claim 1 , wherein the mass ratios of substituted anionic compound/insulin are between 0.5 and 10.

9. The composition as claimed in claim 1 , wherein the concentration of substituted anionic compound is between 1.8 and 36 mg/mL.

10. The composition as claimed in claim 1 , wherein the insulin is human insulin chosen from recombinant human insulins.

11. The composition as claimed in claim 1 , wherein insulin is an insulin analogue chosen from the group consisting of lispro insulin (Humalog®), aspart insulin (Novolog®, Novorapid®) and glulisine insulin (Apidra®).

12. A composition comprising a composition as claimed in claim 1 , wherein the insulin concentration is between 240 and 3000 μM (40 to 500 IU/mL).

13. The composition as claimed in claim 1 , wherein the polyanionic compound is chosen from the group consisting of polycarboxylic acids and the Na + , K + , Ca 2+ or Mg 2+ salts thereof.

14. The composition as claimed in claim 1 , wherein the polyanionic compound is an anionic molecule chosen from the group consisting of citric acid, aspartic acid, glutamic acid, malic acid, tartaric acid, succinic acid, adipic acid, oxalic acid, phosphate, polyphosphoric acids and the Na + , K + , Ca 2+ or Mg 2+ salts thereof.

15. The composition as claimed in claim 1 , wherein the concentration of polyanionic compound is between 2 and 150 mM.

16. The composition as claimed in claim 1 , wherein the substituted anionic compound corresponds to formula I wherein the radical AA is resulting from phenylalanine and the radical R is resulting from tartaric acid, succinic acid or an amino acid chosen from aspartic acid and glutamic acid, the radical R is especially resulting from tartaric acid or succinic acid and in particular n=0 and m=1.

17. The composition as claimed in claim 1 , wherein the substituted anionic compound corresponds to formula I wherein the radical AA is resulting from phenylalanine and the radical R is resulting from succinic acid, tartaric acid or an amino acid chosen from aspartic acid and glutamic acid, n=0 and m=1.

18. The composition as claimed in claim 1 , wherein the substituted anionic compound corresponds to formula I wherein the radical AA is resulting from phenylalanine, n=0, m=1, the radical R is resulting from tartaric acid or succinic acid, in particular from tartaric acid, and bears an acid function.

19. The composition as claimed in claim 1 , wherein the substituted anionic compound corresponds to formula I wherein the radical AA is resulting from phenylalanine, m=0, n=1 or 2, especially n=1, p=3 and E is resulting from TRIS.

20. The composition as claimed in claim 1 , wherein the substituted anionic compound corresponds to formula I wherein the radical AA is resulting from phenylalanine, m=0, n=1 or 2, especially n=1, p=2 and E is resulting from aspartic acid or glutamic acid.

21. The composition as claimed in claim 1 , wherein the substituted anionic compound corresponds to formula I wherein the radical AA is resulting from phenylalanine, m=0, n=1, 2 or 3, especially n=3, p=2 and E is resulting from aspartic acid or glutamic acid.

22. The composition as claimed in claim 1 , wherein the substituted anionic compound corresponds to formula I wherein the radical R is resulting from succinic acid and comprises a carboxylic acid, m=0, n=1, p=3, E is resulting from TRIS, F′ is an amide functi

Assignees

• Adocia

Inventors

• Soula Olivier
• Charvet Richard
• Alluis Bertrand

Classifications

• A61K38/28 Primary

  Insulins · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• A61K9/08

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K47/34

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title